Izervay (Avacincaptad Pegol) for AMD

Overview
Izervay is approved by the U.S. Food and Drug Administration (FDA) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Izervay is also known by its drug name, Avacincaptad Pegol.

Izervay is a complement inhibitor. It is believed to work by inhibiting the complement system, a part of the immune system that, when overactive, can contribute to the progression of AMD by damaging the retina.

How do I take it?
Prescribing information states that Izervay is administered by intravitreal injection (an injection into the eye), typically one per month (approximately every 28 days) for up to 12 months. Dosing amounts and schedules can vary from person to person, based on the assessment of the recommendation of the prescribing health care provider.

Side effects
Common side effects of Izervay include conjunctival hemorrhage (bleeding in the eye), increased intraocular pressure (IOP), blurred vision, and neovascular AMD (new, abnormal blood vessel growth in the eye).

Rare but serious side effects may include endophthalmitis (inflammation of the interior eye tissues) and retinal detachments. People taking this drug should be monitored for these conditions, and any signs of infection or sudden vision changes should be reported to a health care provider immediately.

For more information about this treatment, visit:

Label: Izervay — Avacincaptad Pegol Injection — DailyMed

Izervay — Drugs.com